Tumoral Pyruvate Kinase L/R as a Predictive Marker for the Treatment of Renal Cancer Patients with Sunitinib and Sorafenib

Background and aims: Treatment with tyrosine kinase inhibitors (TKI) like sunitinib and sorafenib has improved the prognosis of patients with metastatic renal cell cancer (mRCC). No predictive marker is available to select patients who will gain from these treatments. Tumoral pyruvate kinase L/R (PK...

Descripción completa

Detalles Bibliográficos
Autores principales: Niinivirta, Marjut, Enblad, Gunilla, Lindskog, Cecilia, Pontén, Fredrik, Dragomir, Anca, Ullenhag, Gustav J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603390/
https://www.ncbi.nlm.nih.gov/pubmed/31289593
http://dx.doi.org/10.7150/jca.30130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603390/
https://www.ncbi.nlm.nih.gov/pubmed/31289593
http://dx.doi.org/10.7150/jca.30130

Ejemplares similares